Dendritic Cells Promoted by Ginseng Saponins Drive a Potent Th1 Polarization

Biomarker Insights

Volumn 3, Issue , 2008, Pages

  Takei, Masao ^a   Tachikawa, Eiichi ^b   Umeyama, Akemi ^c  

^a RESEARCH CENTER BORSTEL   (Germany)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

CTL; dendritic cells; ginseng saponins; terpenoids; Th1 response

Indexed keywords

EID: 85128484892     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S585     Document Type: Review

References (50)

1. Banchereau J., and Steinman R.M. 1998. Dendritic cells and the control of immunity. Nature, 106: 245–52.
2. Lanzavecchia A., and Sallustoa A.F. 2001. Regulation of T cell immunity by dendritic cells. Cell, 106: 263–6.
3. Mellman I., and Steinman R.M. 2001. Dendritic cells: specialized and regulated antigen processing machines. Cell, 106: 2555–8.
4. Steinman R.M., Dhodapkar M. and 2001. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer, 95: 459–73.
5. Forster R., Schubel A., and Breitfeld D. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell, 99: 23–33.
6. Tanaka H., Demeure CE., Rubio M., Delespesse G., and Sarfati M. 2000. Human monocyte-derived dendritic cells induce naïve T cell differentiation into T helper cell type 2 (Th2) or TH1/Th2 effectors: role of stimulator/responder ratio. J. Exp. Med., 192: 405–11.
7. Tao X., Grant C., Constant S., and Bottomly K. 1997. Induction of IL-4-producing CD4+ T cells by antigenic peptides altered for TCR. binding. J. Immunol, 158: 4237–44.
8. Iezzi G., Scotet E., Scheidegger D., and Lanzavecchia A. 1999. The interplay between the duration of TCR. and cytokine signaling determines T cell polarization. Eur. J. Immunol, 29: 4092–101.
9. Kuchroo V.K., Dasa M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., and Glimcheri L.H. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell., 80: 707–13.
10. Lederer J.A., Perez V.L., Desroches L., Kim S.M., Abbas A., and Lichtman A.H. 1996. Cytokine transcriptional events during helper T cell subset differentiation. J. Exp. Med., 184: 397–406.
11. Romagnani S. 1994. Lymphokine production by human T cells in disease state. Annu. Rev. Immunol., 12: 227–57.
12. O'garra A. 2001. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity, 8: 275–8.
13. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med., 184: 747–52.
14. Cella M., Salio M., Sakakibara Y., Langen H., Julkunen I., and Lanzavecchia A. 1999. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med., 189: 821–9.
15. Hartmann G., Weiner G.J., and Krieg A.M. 1999. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. U.S.A., 96: 9305–10.
16. Trinchieri G., and Scott P. 1994. The role of interleukin 12 in the immune response, disease and therapy. Immunol. Today, 15: 460–3.
17. O'garra A., and Murphy K. 1993. T-cell subsets in autoimmunity. Curr. Opin., 5: 880–6.
18. Steinman L. 2007. A brief history of Th17, the first major revision in the Th1/Th2 hypothesis of T cell-mediated tissue damage. Nature Medicine, 13: 139–45.
19. Attele A.S., Wu J.A., and Yunan C.S. 1999. Ginseng pharmacology; multiple constituents and multiple actions. Biochem. Pharmacol., 58: 1685–93.
20. Court W.E. 2000. The Genus Panax. The Netherlands: Harwood Academic Publishers.
21. Ong Y.C., and Yong E.L. 2000. Panax (Ginseng)-Panacea or placebo? Med. Singapore, 29: 42–6.
22. Yun T.K. 2003. Experimental and epidemiological evidence on nonorgan specific cancer preventive effect of Korean ginseng and identification of active compounds. Mut. Res., 523: 63–74.
23. Karikura M., Miyase T., Tanozawa H., Tamiya T., and Takino Y. 1991. Studies on absorption, distribution, excretion and metabolism of ginseng saponins. VII. Comparison of the decomposition modes of ginsenoside-Rb1 and –Rb2 in the digestive tract of rats. Chem. Pharm. Bull, 39: 2357–81.
24. Hasegawa H., Sung J.H., Matumiya S., and Uchiyama M. 1996. Main ginseng saponin metabolites formed by intestinal bacteria. Plant Med., 62: 453–37.
25. Tchikawa E., Kubo K., Hasegawa H., Kashimoto T., Sasaki K., Miyazaki M. et al. 2003. In vitro, inhibition of adrenal catecholamine secretion by steroidal metabolites of ginseng saponins. Biochem. Pharmacol., 24: 1327–33.
26. Claeson P., Andersson R., and Samuelsson G. 1991. T-cadinol: a pharmacologically active constitute of scented myrrh: introductory pharmacological characterization and high field 1H- and 13C-NMR. data. Plant. Med., 57: 352–6.
27. Thulin M., and Claeson P. 1991. The botanical origin of scented myrrh (bissabol or habak hadi). Economic Botany, 45: 487–94.
28. Zygmunt P.M., Larsson B., Sterner O., Vinge E., and Hogestatt E.D. 1993. Calcium antagonistic properties of the sesquiterpene T-cadinol and related substances: structure-activity studies. Pharmacol. Toxicol., 73: 3–9.
29. Kawashima Y., and Samukawa K. 1986. Studies of ginseng. J. Med. Pharm. Soc. WAKAN-YAKU, 3: 236–47.
30. Arihara S., Umeyama A., Bando S., Imoto S., Ono M., Tani M., and Yoshikawa K. 2004. A new abietane and two dimeric abietane diterpens from the Black Heartwood of Cryptomeria japonica. Chem. Pharm. Bull, 52: 354–8.
31. Grage-Griebenow E., Lorenzen D., Fetting R., Flad H.D., and Ernst M. 1993. Phenotypical and functional characterisation of FCγ receptor 1 (CD64)-negative Mo, a minor human mo subpopulation with high accessory and antiviral activity. Eur. J. Immunol., 23: 3126–31.
32. Takei M., Tachikawa E., Hasegawa H., and Lee J.J. 2004. Dendritic cells maturation promoted by M1 and M4, end products of steroidal ginseng saponins metabolized in digestive tracts, drive a potent Th1 polarization. Biochem. Pharmacol., 68: 441–52.
33. Jonuleit H., Kuhn U., and Muller G. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol., 27: 3135–42.
34. Takei M., Nakagawa H., and Endo K. 1993. Mast cell activation by pedicellarial toxin of sea urchin, Tosopneustes pileolus. FEBS Lett, 328: 59–62.
35. Kikuchi M., Nakano M., Inoue Y., and Itho K. 1999. Identification of a SART-1-derived peptide capable of inducing the HLA-A-24-restricted and tumor-specific cytotoxic T lymphocytes. Int. J. Cancer, 81: 459–65.
36. Lee S.P., Tinerney R.J., and Thomas W.A. 1997. Conserved CTL epitopes within EBV latent membrane protein 2; a potential target for CTL-based tumor therapy. J. Immunol., 158: 3325–34.
37. Nakano M., Shuchijo S., Imaizumi T., and Itho K. 1998. A gene encoding antigen peptides of human sequamous cell carcinoma recognized by cytotoxic T lymphocyte. J. Exp. Med., 187: 277–83.
38. Delespesse G., Ohshima Y., Shu U., Yang L.P., Demeure C., Wu Y., Byun D.G., and Sarfat M. 1997. Differentiation of naïve human CD4 T cells into Th2/Th1 effectors. Allergol. Int., 46: 63–72.
39. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., Wolf S.F., and Gately M.K. 1993. Antitumor and anti-metastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 78: 1223–6.
40. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'garra A., and Murphy K.M. 1993. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science, 260: 547–9.
41. Keum Y.S., Han S.S., Chun S., Park K.K., Park J.H., Lee S.K. et al. 2003. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression NF-kappaB activation and tumor promotion. Mutant. Res., 523–34.
42. Wakabayashi C., Hasegawa H., Murata J., and Saiki I. 1997. In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. Oncol. Res., 9: 411–7.
43. Scaglione F., Ferrara F., Dugnani S., Falchi M., Santro G., and Frashini F. 1990. Immunomodulatory effects of two extracts of Panax ginseng C.A. Meyer. Drugs. Exp. Clin. Res., 537–42.
44. Brossart P., Zobywalski A., and Grunebac F. 2000. Tumor necrosis factor A and CD 40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res., 60: 4485–92.
45. Salio M., Cerundolo V., and Lanzavecchia A. 2000. Dendritic cell maturation is induced by mycoplasma infection but not necrotic cells. Eur. J. Immunol., 30: 705–8.
46. Wilson A.D., Bailey M., Williams N.A., and Stokes C.R. 1991. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocya-nin using cholera toxin as an adjuvant. Eur. J. Immunol., 21: 2333–9.
47. Xu-Amano J., Kiyono H., Jackson R.L., Staats H.F., Fujihashi K., Burrows P.D., Elson C.O., Pillai S., and McGhee J.R. 1993. Helper T cells subsets for immunoglobulin a responses; oral immunization with tetanus toxin and cholera toxin as adjuvant selectively induces Th2 cells in mucosa-associated tissues. J. Exp. Med., 178: 1309–20.
48. Gagliardi M.C., Sallusto F., Marinaro M., Langenkamp A., Lanzavecchia A., and De Magistris M.T. 2000. Cholera toxin induces maturation of human dendritic cells and licenses them for Th2 priming. Eur. J. Pharmacol., 30: 2394–403.
49. Nair S., McLaughlin C., Weizer A., Su Z., Boczkowski D., Dannull J., Vieweg J., and Gilboa E. 2003. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol., 171: 6275–82.
50. Albert M.L., Sauter B., and Bhardwaj N. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature, 392: 86–90.